Cosan (CSAN3) Q3 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2025 earnings summary
3 Feb, 2026Executive summary
EBITDA under management reached R$7.4 billion, down from R$8.4 billion in 3Q24, mainly due to MOVE, Haddad, and Raízen performance and one-off effects.
Net income was negative R$1.2 billion at the corporate level, compared to a profit of R$293 million in 3Q24, impacted by lower EBITDA and higher financial expenses.
Net debt at the corporate level reached R$18.2 billion, up from R$17.5 billion in 2Q25, with DSCR at 1.0x LTM.
Major public equity offerings raised R$10.5 billion, significantly improving the capital structure and reducing holding company indebtedness.
Management transition and board changes align with new shareholder agreements and future strategy.
Financial highlights
EBITDA decreased by R$1 billion compared to Q3 2024, with adjusted EBITDA under management at R$7.4 billion, down 11% year-over-year.
Net income was negative R$1.2 billion for the quarter.
Dividends and interest on capital received dropped 86% year-over-year to R$48 million.
Debt service coverage ratio at 1.0x; gross debt stable at R$21.6 billion, net debt slightly higher.
Cash and cash equivalents ended at R$3.5 billion, down from R$3.98 billion at the start of the period.
Outlook and guidance
Focus on integrating new shareholders, further deleveraging, and cost discipline to bring debt close to zero.
No immediate pressure for asset sales; divestments will be paced to maximize value.
Ongoing discussions with Shell to resolve Raízen's capital structure within six months.
Forward-looking statements are subject to market, economic, and operational risks, including currency fluctuations and changes in consumer demand.
Latest events from Cosan
- EBITDA and net income fell, but leverage was reduced through asset sales and liability management.CSAN3
Q4 202510 Mar 2026 - Net debt dropped to R$17.5B after Vale sale; EBITDA fell 30% as Moove and Raízen struggled.CSAN3
Q1 20253 Feb 2026 - Net loss of R$9.4 billion driven by impairments, with Rumo and Compass showing EBITDA growth.CSAN3
Q4 20243 Feb 2026 - EBITDA fell to R$6.0bn, net loss widened, and leverage rose to 3.4x as segment results diverged.CSAN3
Q2 20253 Feb 2026 - EBITDA grew to R$8.2B, net income fell to R$293M, and management refocused on core business.CSAN3
Q3 20243 Feb 2026 - EBITDA up 15% to R$7.1bn, net loss narrows, but Rumo impairment weighs on results.CSAN3
Q2 20243 Feb 2026